Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source
No articles found.
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...
Phio Pharmaceuticals is focused on developing t...
Quadrant Biosciences is an epigenetic diagnostics company with a focus on the earl...
Quadrant Biosciences is an epigenetic diagnosti...
Shionogi & Co., Ltd. engages in the research, development, supply, manufacture, an...
Shionogi & Co., Ltd. engages in the research, d...
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indicatio...
Kamada Ltd. is focused on plasma-derived protei...
Vericel is a leader in advanced therapies for the sports medicine and severe burn ...
Vericel is a leader in advanced therapies for t...
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...
MacroGenics is a clinical-stage biopharmaceutic...
Conatus Pharmaceuticals is a biotechnology company focused on the development and ...
Conatus Pharmaceuticals is a biotechnology comp...
GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...
GENFIT is a late-stage biopharmaceutical compan...
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Cara Therapeutics is a clinical-stage biopharma...
Novan, Inc. is a clinical development-stage biotechnology company focused on lever...
Novan, Inc. is a clinical development-stage bio...
Join the National Investor Network and get the latest information with your interests in mind.